4277-02-5 Usage
Uses
Used in Plasticizer Industry:
1,2-Benzenedicarboxylic acid, 3,5-dinitrois used as a plasticizer in the production of polyvinyl chloride (PVC). It enhances the flexibility and workability of PVC, making it suitable for various applications such as pipes, films, and cables.
Used in Dye Manufacturing:
1,2-Benzenedicarboxylic acid, 3,5-dinitrois used in the manufacturing of dyes, where its chemical properties contribute to the color and stability of the dyes produced. Its presence in dye formulations can improve the performance and durability of colored products.
Used in Perfumery:
1,2-Benzenedicarboxylic acid, 3,5-dinitrois utilized in the production of perfumes and fragrances. Its unique chemical structure allows it to contribute to the scent profile of various fragrances, enhancing their aroma and longevity.
Used in Pharmaceutical Industry:
1,2-Benzenedicarboxylic acid, 3,5-dinitrois used in the manufacturing of certain pharmaceuticals, where its properties can be harnessed for therapeutic purposes. Its presence in drug formulations can contribute to the efficacy and stability of the final product.
However, due to the toxic effects of 1,2-Benzenedicarboxylic acid, 3,5-dinitro-, strict safety measures should be implemented in its handling, storage, and disposal to minimize exposure and potential health risks. Long-term exposure to 1,2-Benzenedicarboxylic acid, 3,5-dinitro- can cause irritation to the skin, eyes, and respiratory system, and may lead to potential reproductive and developmental toxicity.
Check Digit Verification of cas no
The CAS Registry Mumber 4277-02-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,2,7 and 7 respectively; the second part has 2 digits, 0 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 4277-02:
(6*4)+(5*2)+(4*7)+(3*7)+(2*0)+(1*2)=85
85 % 10 = 5
So 4277-02-5 is a valid CAS Registry Number.
4277-02-5Relevant articles and documents
S6K1 PROTEIN KINASE INHIBITORS AS CANCER THERAPEUTICS
-
Paragraph 0068; 0117, (2021/10/22)
The present disclosure relates to compounds that act as protein kinase inhibitors, especially RPS6K1 and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ and/or HER2+ breast cancer, prostate cancer, lung cancer, and metastatic cancer.
